Literature DB >> 2495035

PGE1 accelerates thrombolysis by tissue plasminogen activator.

D E Vaughan1, S R Plavin, A I Schafer, J Loscalzo.   

Abstract

Platelets are an active element in the generation of thrombus and may influence rates of thrombolysis during the administration of plasminogen activators. To assess the potential importance of platelet aggregation in the thrombolytic response to plasminogen activators, we measured rates of thrombolysis induced by tissue plasminogen activator in the presence and absence of a coinfusion of prostaglandin E1 in a rabbit jugular vein model of thrombosis. Rates of lysis were quantified by measuring the half-time for lysis of the thrombus. At all concentrations of tissue plasminogen activator used, prostaglandin E1 markedly reduced the half-time for clot lysis and enhanced somewhat the overall extent of thrombolysis, without affecting significantly either the degree of fibrinogen depletion or the animals' mean arterial pressures. These effects on thrombolytic efficacy were accompanied by ex vivo evidence of platelet inhibition. These data suggest that the antiplatelet prostaglandin E1 may be a very useful adjunctive agent in thrombolytic therapy primarily by virtue of the significant improvement in the rate of thrombolysis that its use affords.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495035

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

2.  Protective effects of prostaglandin E1 on human umbilical vein endothelial cell injury induced by hydrogen peroxide.

Authors:  Wen-tong Fang; Hong-jian Li; Liao-sheng Zhou
Journal:  Acta Pharmacol Sin       Date:  2010-03-22       Impact factor: 6.150

3.  Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.

Authors:  Joon Sup Song; Jong Jin Seo; Hyung Nam Moon; Thad Ghim; Ho Joon Im
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

4.  Veno occlusive disease: update on clinical management.

Authors:  M Senzolo; G Germani; E Cholongitas; P Burra; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 5.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.